The value of the U.S. breast tissue marker market is expected to increase modestly over the forecast period. Growth in the value of the market will be driven by increasing unit sales and limited by ASP erosion. The increasing incidence of breast cancer and utilization of breast tissue markers in percutaneous breast biopsies as well as axillary lymph node marking are expected to fuel unit sales growth over the next seven years. ASP erosion will be driven by commoditization of breast tissue markers with lower clinical value.
Breast tissue markers are placed during roughly 80% of percutaneous breast biopsy procedures. Percutaneous breast biopsy procedures are typically performed using ultrasound guidance, stereotactic guidance or Magnetic Resonance Imaging (MRI) guidance. The volume of ultrasound guided percutaneous biopsy procedures performed annually in the U.S. is expected to increase over the forecast period, while the number of stereotactic-guided breast biopsy procedures is expected to decline.
MRI-guided percutaneous breast biopsy procedure volume is expected to remain relatively stable through 2022. In the past, most breast tissue markers were designed for use with specific biopsy needles. In the future, an increasing number of breast tissue markers are expected to be designed for use with a wide range of biopsy needles.
Key Topics Covered:
1. Executive Summary 1.1 U.S. Breast Tissue Markers & Breast Localization Wire Market Overview 1.2 Competitive Landscape 1.3 Market Trends 1.4 Key Market Developments 1.5 Markets Included 1.6 Version History
2. Research Methodology 2.1 Research Scope 2.2 9-Step Methodology
3. Breast Tissue Marker Market 3.1 Market Analysis And Forecast 3.1.1 Breast Tissue Marker Market 3.2 Drivers And Limiters 3.2.1 Market Drivers 3.2.2 Market Limiters 3.3 Competitive Market Share Analysis